

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Examiner: To Be Assigned
)	
Bush et al.)	Group Art Unit: 1636
)	
Serial No.: 10/574,167)	Docket No.: 8028-007-US
)	
Filed: March 29, 2006)	
)	
For: USE OF CELL LINES TO)	
PRODUCE ACTIVE THERAPEUTIC)	
PROTEINS)	

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This document is a Second Supplemental Information Disclosure Statement to the above-cited patent application.

Attached is at least one form PTO/SB/08A/B listing documents believed relevant to the subject application. The submission of the following information is not intended, nor should it be construed, to constitute an admission that any patent, article, or other information referred to herein is "prior art" unless specifically designated as such. In accordance with 37 C.F.R. § 1.97(b), the filing of this information shall not be construed to mean that a search has been made or that no other material information may exist. Neither should its submission be construed to indicate that a thorough search should not be conducted by the Examiner.

It is believed that this disclosure complies with the requirements of 37 C.F.R. § 1.96, § 1.97, and § 1.98 and the Manual of Patent Examining Procedures §

It is believed that this disclosure complies with the requirements of 37 C.F.R. § 1.96, § 1.97, and § 1.98 and the Manual of Patent Examining Procedures § 707.05(b). If for some reason the Examiner considers otherwise, it is respectfully requested that the undersigned be telephoned at (858) 450-0099 x302 so that any deficiencies can be remedied.

This Second Supplemental Information Disclosure Statement is being submitted before the mailing date of an Office Action on the merits for the above-identified patent application. Accordingly, no fee is due for the filing of this Information Disclosure Statement under 37 C.F.R. § 1.97(b)(2).

A copy of each document is enclosed, except for issued United States patents and published United States patent applications pursuant to 37 C.F.R. § 1.98(a)(2)(ii). Some of the documents may have markings thereon. No significance is to be attached to the markings. These documents are not necessarily analogous art. Additionally, the order of the following documents is to be accorded no particular import, as the order thereof is completely fortuitous.

It is respectfully requested that these documents be: (1) fully considered by the Patent and Trademark Office during the prosecution of this application; and (2) represented on any patent which may issue on the application. Applicant respectfully requests that copies of the forms PTO/SB/08A/B, as considered and initialed by the Examiner, be returned with the next communication.

PCT Patent Application Publication No. WO 99/40793 by Triglia et al., published on August 19, 1999.


A publication, M. Kosuga et al., "Strong, Long-Term Transgene Expression in Rat Liver Using Chicken β -Actin Promoter Associated with

Cytomegalovirus Immediate-Early Enhancer (CAG Promoter)," Cell Transplantation 9:
675-680 (2000).

A publication, J.-H. Lee et al., "Production and Characterization of
Immortalized Rat Hepatocytes Secreting Hepatocyte Growth Factor/Scatter Factor,"
Hepato-Gastroenterology 47: 978-983.

A publication, A.L. Morris et al., "In Vitro Induction of Cytochrome
P450S and Drug Transporters Using the Fa2N-4 Immortalized Human Hepatocyte Line,"
Drug Metabol. Rev. 35 (Suppl. 2): 125 (2003).

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Michael B. Farber', written over a horizontal line.

Michael B. Farber, Ph.D., Esq.
Reg. No.: 32,612

Date: November 20, 2006

CATALYST LAW GROUP, APC
9710 Scranton Road, Suite 170
San Diego, California 92121
(858) 450-0099
(858) 450-9834 (Fax)